LIXT News and Press, Lixte Biotechnology Holdings Inc.

Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the &#...

Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ȁ...

LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( ...

2024-06-03 10:21:32 ET More on Lixte Biotechnology Holdings, Inc. Lixte stock soars on preclinical data for lead drug LB-100 Financial information for Lixte Biotechnology Holdings, Inc. Read the full article on Seeking Alpha For further details see: Lixte...

PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunothe...

Publishing of Findings in Recent Pre-Clinical Study for LIXTE’s Proprietary Compound, LB-100, in New Field of Cancer Biology, “Activation Lethality” Presentation at MedInvest Biotech and Pharma Investor Conference Co-Sponsorship/Presentation of Wor...

2024-05-09 13:53:27 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lixte Biotech Hldgs (NASDAQ: LIXT ) just reported results for the first quarter of 2024. Lixte Biotech Hldgs reported earnings per share of -43 cents. The company did ...

Recent Findings Relate to LIXTE’s Lead Clinical Compound, LB-100, to be Presented at Workshop on May 9 and 10 at Harvard’s Dana Farber Cancer Institute in Boston PASADENA, CA, May 08, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or ...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

2024-04-24 17:14:01 ET A California-based %Biotech company is finding pretty serious success on Wednesday a day after the company filed a registration statement covering the potential sale of up to $50 million mixed shelf offering, which covered common shares, preferred shares, debt sec...